CANbridge Pharmaceuticals Inc. Statistics
Want to see HK:1228 full AI Analyst Report?
CANbridge Pharmaceuticals Inc. (1228) Stock Statistics & Valuation Metrics
Total Valuation
CANbridge Pharmaceuticals Inc. has a market cap or net worth of HKD 968.31M. The enterprise value is HKD 1.45B.
- Market Cap
- HKD 968.31M
- Enterprise Value
- HKD 1.45B
Share Statistics
CANbridge Pharmaceuticals Inc. has 597,723,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 597,723,300
- Owned by Insiders
- ―
- Owned by Institutions
- 0.18%
Financial Efficiency
CANbridge Pharmaceuticals Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 32.86%.
- Return on Equity (ROE)
- -0.04
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 32.86%
- Return on Capital Employed (ROCE)
- 0.32
- Revenue Per Employee
- 1.28M
- Profits Per Employee
- 379.95K
- Employee Count
- 39
- Asset Turnover
- 0.30
- Inventory Turnover
- 0.65
Valuation Ratios
The current PE Ratio of CANbridge Pharmaceuticals Inc. is -8.72. CANbridge Pharmaceuticals Inc.’s PEG ratio is -0.03.
- PE Ratio
- -8.72
- PS Ratio
- 10.50
- PB Ratio
- -3.96
- Price to FCF
- -5.22
- Price to Operating Cash Flow
- -6.93
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, CANbridge Pharmaceuticals Inc. had revenue of 49.98M and earned 14.82M in profits. Earnings per share was 0.03.
- Revenue
- 49.98M
- Gross Profit
- 36.55M
- Operating Income
- -92.70M
- Pretax Income
- 14.82M
- Net Income
- 14.82M
- EBITDA
- -80.55M
- Earnings Per Share (EPS)
- 0.03
Cash Flow
In the last 12 months, operating cash flow was -111.98M and capital expenditures -42,000, giving a free cash flow of -112.02M billion.
- Operating Cash Flow
- -111.98M
- Free Cash Flow
- -112.02M
- Free Cash Flow per Share
- -0.20
Dividends & Yields
CANbridge Pharmaceuticals Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.17%
- Earnings Yield
- -10.50%
Stock Price Statistics
- Beta
- 0.49
- 52-Week Price Change
- -22.12%
- 50-Day Moving Average
- 1.86
- 200-Day Moving Average
- 2.19
- Relative Strength Index (RSI)
- 37.07
- Average Volume (3m)
- 659.13K
Important Dates
CANbridge Pharmaceuticals Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
CANbridge Pharmaceuticals Inc. as a current ratio of 0.24, with Debt / Equity ratio of -4.71%
- Current Ratio
- 0.24
- Quick Ratio
- 0.20
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.63
- Interest Coverage Ratio
- -42.67
Taxes
In the past 12 months, CANbridge Pharmaceuticals Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CANbridge Pharmaceuticals Inc. EV to EBITDA ratio is -5.98, with an EV/FCF ratio of -4.69.
- EV to Sales
- 9.43
- EV to EBITDA
- -5.98
- EV to Free Cash Flow
- -4.69
- EV to Operating Cash Flow
- -4.69
Balance Sheet
CANbridge Pharmaceuticals Inc. has HKD 88.10M in cash and marketable securities with HKD 28.81M in debt, giving a net cash position of HKD 59.29M billion.
- Cash & Marketable Securities
- HKD 88.10M
- Total Debt
- HKD 28.81M
- Net Cash
- HKD 59.29M
- Net Cash Per Share
- HKD 0.10
- Tangible Book Value Per Share
- -HKD 0.43
Margins
Gross margin is 71.47%, with operating margin of -177.65%, and net profit margin of -146.41%.
- Gross Margin
- 71.47%
- Operating Margin
- -177.65%
- Pretax Margin
- -146.41%
- Net Profit Margin
- -146.41%
- EBITDA Margin
- -157.69%
- EBIT Margin
- -177.65%
Analyst Forecast
The average price target for CANbridge Pharmaceuticals Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -8.00%
- EPS Growth Forecast
- 51.26%
Scores
- Smart Score
- 4
- AI Score
- 49

